Companies / Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Company- Registered trials
- 290
- Ongoing
- 36/ 12%
- Completed
- 223
- Related drugs
- 3
- Related conditions
- 10
Clinical trial landscape
290 registered studies reference this company or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 3 | 88 | 16 | 65 | |
| Phase 1 | 81 | 5 | 75 | |
| Phase 2 | 71 | 4 | 57 | |
| Unknown | 19 | 2 | 12 | |
| Phase 1/2 | 10 | 3 | 6 | |
| Phase 4 | 9 | 4 | 3 | |
| Phase 2/3 | 7 | 2 | 3 | |
| Not applicable | 5 | 0 | 2 | |
| All phases | 290 | 36 | 223 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Recent developments
| Biotech Deal Boom, Regulatory Advances, and CRISPR Pipeline Progress | theglobeandmail.com ↗ | |
| Health Canada Accepts Vertex's Suzetrigine New Drug Submission for Acute Pain | pubmed.ncbi.nlm.nih.gov ↗ | |
| Moderna Narrows Q2 Loss; Flu Vaccine Decision and Norovirus Trial Setback in Focus | theglobeandmail.com ↗ | |
| FBT Biotech ETF Tops Category Returns, Outpaces IBB | theglobeandmail.com ↗ | |
| IBBQ vs IBB: Biotech ETFs Show Strong Returns but High Volatility | aol.com ↗ | |
| FDA Grants Full Approval to Novartis' Fabhalta (iptacopan) for IgA Nephropathy | firstwordpharma.com ↗ | |
| Pain Market Valued at $4.5B in 2025, Driven by Non-Opioid Innovation and Pipeline Expansion | expresspharma.in ↗ | |
| CRISPR vs Moderna: Market Cap Gap and Pipeline Outlook Contrast | msn.com ↗ | |
| Vertex Pharmaceuticals: Cystic Fibrosis Monopoly and Pipeline Fuel Long-Term Growth | cnbc.com ↗ | |
| Vertex Kidney Drug Povetacicept Hits Phase 3 Goal, FDA Grants Rolling Review | statnews.com ↗ |
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.